Core Viewpoint - The company plans to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement, indicating a strategic financial investment in the long-term potential of innovative drugs [1][2] Group 1: Investment Details - The company intends to subscribe for no more than 63,157,895 new shares of Haihe Pharmaceutical at a price of 4.75 yuan per share [1] - Post-investment, the company's shareholding in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1] Group 2: Target Company Overview - Haihe Pharmaceutical focuses on the discovery, development, production, and commercialization of innovative drugs, particularly in the oncology field [1] - The company has developed over ten research pipelines, with three products already launched in China and Japan, and five products currently in clinical research [1] - Haihe Pharmaceutical's pipelines target various cancers and chronic diseases, aiming to meet unmet clinical needs [1] Group 3: Strategic Intent - The investment is aimed at ensuring stable operations of the main business while seeking reasonable financial returns and exploring opportunities in emerging industries [2]